Stockscreener 앱 받기
59.13
0.15%
-0.09
시간 외 거래:
58.80
-0.33
-0.56%
전일 마감가:
$59.22
열려 있는:
$57.06
하루 거래량:
2.01M
Relative Volume:
1.70
시가총액:
$4.72B
수익:
$541.74M
순이익/손실:
$88.01M
주가수익비율:
54.44
EPS:
1.0862
순현금흐름:
$155.34M
1주 성능:
+3.79%
1개월 성능:
+15.29%
6개월 성능:
+42.24%
1년 성능:
+144.14%
1일 변동 폭
$57.06
$59.19
1주일 범위
$55.62
$60.82
52주 변동 폭
$22.61
$60.91
Veracyte Inc Stock (VCYT) Company Profile
명칭
Veracyte Inc
전화
(650) 243-6300
주소
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, IDXX, NTRA, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
59.13 | 4.73B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
532.48 | 201.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.83 | 145.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
567.44 | 45.44B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
271.39 | 38.64B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
131.46 | 38.44B | 7.23B | 1.41B | 1.09B | 4.979 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 개시 | Jefferies | Buy |
| 2025-12-02 | 재개 | Morgan Stanley | Underweight |
| 2025-10-20 | 개시 | Canaccord Genuity | Hold |
| 2025-03-20 | 개시 | Craig Hallum | Buy |
| 2024-12-05 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-16 | 개시 | UBS | Buy |
| 2024-10-10 | 개시 | Guggenheim | Buy |
| 2024-02-23 | 재확인 | Needham | Buy |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2021-11-18 | 재개 | Goldman | Buy |
| 2021-06-15 | 개시 | Raymond James | Outperform |
| 2021-02-18 | 재개 | Needham | Buy |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | 개시 | Morgan Stanley | Underweight |
| 2019-07-31 | 개시 | Lake Street | Buy |
| 2019-07-02 | 개시 | Needham | Buy |
| 2018-11-29 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Janney | Neutral → Buy |
| 2017-11-07 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-11-07 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | 재개 | BTIG Research | Buy |
| 2016-11-14 | 재개 | Leerink Partners | Outperform |
| 2015-12-18 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-11 | 재확인 | Leerink Partners | Outperform |
| 2013-11-26 | 개시 | William Blair | Outperform |
모두보기
Veracyte Inc 주식(VCYT)의 최신 뉴스
This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
A Look at Veracyte Inc (VCYT) After 5.1% Gain -- GF Value $38.30 vs Price $59.51 - GuruFocus
Piper Sandler Initiates Veracyte(VCYT.US) With Buy Rating, Announces Target Price $66 - Moomoo
Piper Sandler initiates Veracyte stock with overweight rating By Investing.com - Investing.com Nigeria
Piper Sandler Initiates Veracyte at Overweight With $66 Price Target - marketscreener.com
VCYT Initiated Coverage by Piper Sandler -- Rating Overweight - GuruFocus
CCORF Maintains Veracyte(VCYT.US) With Hold Rating, Raises Target Price to $60 - Moomoo
VCYT Maintained by Canaccord Genuity -- Price Target Raised to $60 - GuruFocus
Here's how much you'd have if you invested $1000 in Veracyte a decade ago - MSN
Morgan Stanley Maintains Veracyte(VCYT.US) With Sell Rating, Raises Target Price to $47 - Moomoo
Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026 - BioSpace
A Look at Veracyte Inc (VCYT) After 5.5% Gain -- GF Value $38.24 vs Price $59.30 - GuruFocus
VCYT Maintained by Morgan Stanley -- Price Target Raised to $47. - GuruFocus
Press Release: Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026 - Moomoo
St. Pete woman seeks $10M in discrimination lawsuit against employer - Business Observer
Veracyte, Inc. Stock 12‑Month Price Target Raised to $55.8, Implies 1% Downside - TradingView
Jefferies Maintains Veracyte(VCYT.US) With Buy Rating, Raises Target Price to $70 - Moomoo
Does Veracyte’s (VCYT) Russell Value Index Debut Redefine Its Small-Cap Defensive Narrative? - simplywall.st
Veracyte Inc updates investors on breast cancer test coverage. Nasdaq-listed diagnostics group build - ad-hoc-news.de
All You Need to Know About Veracyte (VCYT) Rating Upgrade to Strong Buy - Yahoo Finance
Is Veracyte (VCYT) Fully Valued As Insider Selling And Index Additions Draw Attention? - simplywall.st
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy - AOL.com
Veracyte Inc (VCYT) Stock Down 3.2% but Still Overvalued -- GF S - GuruFocus
Veracyte (VCYT) Edges Higher, Approaches Key Resistance Amid Steady TradingALMA Signal - dars.gov.et
Veracyte Inc (NASDAQ:VCYT) Fits the Affordable Growth Profile - ChartMill
A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction. - Yahoo Finance
Veracyte Inc (VCYT) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Veracyte Stock Surges 117% in a Year: What's Driving the Rally? - TradingView
Veracyte Inc (VCYT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
VCYT Maintained by Guggenheim -- Price Target Raised to $65 - GuruFocus
Veracyte Price Target Raised to $65.00/Share From $45.00 by Guggenheim - Moomoo
Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 2000 Value Benchmark - marketscreener.com
Veracyte (VCYT) Enters Multiple Russell Indexes Is Its Small-Cap Profile Quietly Changing? - simplywall.st
Price to book forward of Veracyte, Inc. – NASDAQ:VCYT - TradingView
Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 2000 Value-Defensive Index - marketscreener.com
Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 3000E Value Benchmark - marketscreener.com
Price to sales forward of Veracyte, Inc. – NASDAQ:VCYT - TradingView
Enterprise value to EBIT forward of Veracyte, Inc. – NASDAQ:VCYT - TradingView
Veracyte, Inc.(NasdaqGM: VCYT) added to Russell 3000 Value Benchmark - marketscreener.com
Price to earnings forward of Veracyte, Inc. – NASDAQ:VCYT - TradingView
Price to earnings forward of Veracyte, Inc. – FWB:12V - TradingView
Price to sales forward of Veracyte, Inc. – FWB:12V - TradingView
Enterprise value to revenue forward of Veracyte, Inc. – FWB:12V - TradingView
Price to book forward of Veracyte, Inc. – FWB:12V - TradingView
Enterprise value to EBITDA forward of Veracyte, Inc. – NASDAQ:VCYT - TradingView
What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rally - Yahoo Finance
Veracyte, Inc. Actuals & Estimates (TRADEGATE:12V) - TradingView
Veracyte, Inc. Actuals & Estimates (MUN:12V) - TradingView
Veracyte, Inc. Actuals & Estimates (DUS:12V) - TradingView
Q1 2025 Veracyte Inc Earnings Call Transcript - GuruFocus
Veracyte Inc (VCYT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.61%
1.88%
자본화:
|
볼륨(24시간):